Center for Innovative Study Design
The Stat4Onc Annual Symposium is a three-day symposium that aims to bring oncologists and statisticians together to share new research, discuss novel ideas, ask questions and provide solutions for cancer clinical trials and research. In the era of big data, precision medicine, and genomics and immune-based oncology, it is crucial to provide a platform for interdisciplinary dialogues among clinical and quantitative scientists. An important aspect of Stat4Onc is the participation of researchers in oncology and statistics across academia, industry and regulatory agencies.
Stanford Center for Innovative Study Design, Department of Biomedical Data Science, Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford SPARK, Stanford University
- University of Chicago Medicine Comprehensive Cancer Center, Department of Public Health Sciences, the University of Chicago
- Department of Statistics, the University of Connecticut
- Knight Cancer Institute, Oregon Health and Sciences University
We are soliciting additional support for this event. Please contact Professor Ying Lu, firstname.lastname@example.org.
May 6-8, 2021
Virtual Online Meeting by Stanford University, CA, USA
This event will include:
- Real-World Data and Evidence in Drug Development and Regulatory Submission: Statistical Considerations
- Innovative Designs for Early Phase Oncology Trials
- Plenary Panel Discussions
- Master Protocols on Complex Trial Designs: Finding the Right Treatment for Patients
- Six Invited Sessions
- Biomarker Driven Methodology for Clinical Applications
- Innovations in Trial Design for Cancer Drug Evaluations
- Complex Innovative Design and Applications to Rare Disease Research
- Real World Evidence in Oncology Research
- URM: Representativeness in Oncology Research
- Evaluation and Level of Evidence for Combination Cancer Treatments
Follow the link below for registration information about rates, policies, and deadlines.
The idea of a unique conference that brings statisticians and oncologists together to discuss the challenges in oncology was initiated in 2015 during discussions between Yuan Ji (University of Chicago) and Professors Ying Lu (Stanford). The first symposium was held in 2017 at Stanford University . It was sponsored jointly by Stanford University and the University of Chicago. The second symposium was held in 2018 at the University of Chicago. At that time, we extended our partnership to include the University of Connecticut and chose OncoStat as the symposium name. The third symposium was held in 2019 at the University of Connecticut and renamed our symposium Stat4Onc. In 2020, we further extended our partnership to include the Oregon Health and Science University. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University.
Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. For the safety of our participants and in view of current pandemic condition, the 2021 Symposium will be held online on May 6-8, 2021.
There will be poster viewing session from May 6-8, 2021. Topics related to interface between biostatistics and oncology are welcome. We encourage researchers, in particular young researchers and trainees in academia, industry and government to submit the title and one-page abstract of the posters for review on or before April 14, 5PM PT. Posters should depict scientific research projects with relevant data. Email confirming acceptance of abstracts for poster presentation will be sent on or before April 19, 5PM PT. Posters need to be submitted on or before April 26 5PM PT in pdf or ppt. Decisions of the top 5 selected for oral presentation will be sent by email on April 30th 5PM PT. Registration fee of the selected oral presentations will be refunded for one presenter per poster. Inquiries about the poster session can be made via email to email@example.com.
Featured Keynote Speakers
Peter Bross, MD, Center for Biological Evaluation and Research, US Food and Drug Administration
Peter Bross, MD, is a clinical oncology team leader in the FDA Center for Biological Evaluation and Research (CBER), Office of Tissue and Advanced Therapies (OTAT) and previously worked as a clinical reviewer in the Division of Oncology Drug Products in the Center for Drug Evaluation and Research (CDER). Dr. Bross has expertise in the design and analysis of clinical oncology trials of cellular, tissue and gene therapies, especially cancer vaccines, combination therapies, and companion diagnostics. As a regulatory reviewer, he has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, including oncolytic viruses, cellular immunotherapies, targeted kinase inhibitors, proteasome inhibitors and an antibody-drug conjugate. He has presented FDA perspectives at professional meetings and review findings at FDA advisory committee meetings and has authored several manuscripts on regulatory topics. Dr. Bross is a graduate of University of Virginia Medical School and trained in Hematology and Oncology at The George Washington University and has been at FDA since 1999.
Amanda Bruegl, MD, Oregon Health and Sciences University
Amanda Bruegl is a Citizen of Oneida Nation and is a Gynecologic Oncologist in the department of OB/Gyn at Oregon Health and Science University. She completed her fellowship in gynecologic oncology at MD Anderson Cancer Center and has been at OHSU since that time. She is the Associate Director of the Education Core for the Northwest Native American Center of Excellence, a recipient of the Robert Wood Johnson Harold Amos Minority Faculty Development Award, and has research interests in gynecologic cancer prevention in American Indian/Alaska Native women.
Shein-Chung Chow is a professor in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine. Dr. Chow is also a professor of clinical sciences at Duke-National University of Singapore Graduate Medical School.
His research interests includes statistical methodology development and application in the area of biopharmaceutical/clinical statistics such as bioavailability and bioequivalence, clinical trials, bridging studies, medical devices, and translational research/medicine. Most recently, he is interested in statistical methodology development for the use of adaptive design methods in clinical trials and methodology development for assessment of biosimilarity of follow-on biologics. In addition, he is interested in methodology development for statistical evaluation of traditional Chinese medicine (TCM) clinical trials.
Laura Esserman, MD, University of California, San Francisco
Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.
Christina Yau, PhD, University of California, San Francisco
Dr. Yau is an Assistant Adjunct Professor of Surgery at the University of California, San Francisco (UCSF).
James Reimann, PhD, Genentech/Roche
James Reimann is the Vice President and Global Head of Oncology Biostatistics & Patient Centered Outcomes Research (PCOR) at Genentech. James has spent more than 25 years with Genentech/Roche, having joined the company in 1994. In his current role, he oversees biostatistics and PCOR for the oncology development pipeline, from the entry into human studies through the regulatory approvals process. He holds a PhD, Statistics from the University of California, Berkeley.
Scientific Program Committee
- Yuan Ji (Co-Chair), Ph.D., The University of Chicago, IL (YJi@health.bsd.uchicago.edu)
- Ying Lu (Co-Chair), Ph.D., Stanford University, CA (firstname.lastname@example.org)
- Shivaani Kummar (Co-Chair), M.D., Oregon Health and Science University, OR (email@example.com)
- Ming-Hui Chen (Co-Chair), Ph.D., The University of Connecticut (firstname.lastname@example.org)
- Mei-yin Polley, The University of Chicago (email@example.com)
- Lu Tian, Ph.D., Stanford University
- Manisha Desai, Ph.D., Stanford University (firstname.lastname@example.org)
- Kristen May Cunanan, Ph.D., Stanford University
- Tze Lai, Ph.D., Stanford University (email@example.com)
Webmaster: Heeju Lim (firstname.lastname@example.org)
Administrative Support: Malu Robles (email@example.com)